TT-00420 (Tinengotinib) vs chemo for bile duct cancer
Part of Cancer clinical trials.
This trial tests a new targeted drug called TT-00420 (tinengotinib) against standard chemotherapy for people with a specific type of bile duct cancer that has a change in the FGFR2 gene. The drug is designed to target and block cancer cells with that gene change, possibly slowing the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver).
- Your cancer must be stage III or IV and cannot be removed by surgery.
- You have already tried one line of chemotherapy combined with immunotherapy, and your cancer has come back or gotten worse.
- Your tumor must have a specific change in the FGFR2 gene (fusion, rearrangement, or mutation), confirmed by a central lab.
- You must have at least one tumor that can be measured on a scan, and you must be in good overall health (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy drugs for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that hasn't been treated yet. It aims to see if adding a targeted therapy (lenvatinib) improves outcomes.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests whether matching targeted therapy to the genetic changes in your cancer can lower the chance of it coming back after surgery. You would first have your tumor tested for specific alterations, and if one is found, you may receive a drug that targets it.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.